Empowering technologies such as PropTech, CleanTech and MedTech are reshaping industries, accelerating innovation and driving new ways of working.
Macro trends - from the pursuit of net zero to demographic shifts and digital transformation - are influencing how organisations adopt and integrate technology.
Clients face a range of challenges, from meeting regulatory requirements and achieving sustainability targets, to harnessing data and digital tools for growth. Many seek guidance on deploying technology in complex environments, whether to decarbonise operations, transform real estate, or deliver better healthcare outcomes.
Stephenson Harwood’s sector specialists work closely with clients to address these needs. Our team supports developers and users of empowering technologies across our key sectors, offering practical advice on commercial, regulatory, and operational issues. For example, clients benefit from support on decarbonisation technologies in energy and infrastructure, digital transformation in real estate, and the integration of digital health solutions in life sciences and healthcare.
Clients choose us for our deep sector knowledge, collaborative approach, and ability to deliver clear, commercially focused advice. Our future-facing perspective and cross-sector expertise enable clients to unlock value, manage risk, and achieve strategic goals in a rapidly evolving landscape.
Our Services
- BW Group
Advising on its acquisition of 100% of Hawaiki Submarine Cable and International Connectivity Services. The investment into Hawaiki Nui and Datagrid is the first submarine cable to directly interconnect Singapore, Indonesia, Australia, New Zealand and the US, is Australasia’s first carbon-neutral hyperscale datacentre, powered by 100% green energy. - Shape
Advising on the incorporation and joint venture for the formation of Shape, a digital energy services company, created by Mitsui & Co, Modec Inc, and McKinsey. Shape pursuits impact-driven innovation, such as Greenhouse Gas reduction solution under R&D Phase, aimed at contributing towards a net zero society. - Finnfund
Advising Finnfund on its investment in KaiOS Technologies, the leading mobile operating system for smart feature phones, to help bring affordable mobile connections to Sub-Saharan Africa and work towards boosting digitalisation. This investment is classified as a 2X Challenge eligible gender investment, supporting women to close the digital divide that exists across lower-middle income countries.
We also advised Finnfund on its investment in the telecom tower sector in Indonesia.
- GE Healthcare
Advised GE Healthcare on the acquisition of Zionexa. GE Healthcare is a medical technology, pharmaceutical diagnostics, and digital solutions company; Zionexa is an innovator of in-vivo oncology and neurology biomarkers that help enable more personalised healthcare. - UCB
In addition to our longstanding role advising UCB in relation to a range of day-to-day trading agreements (including MSAs, Platform Technology collaborations and Sponsored Research Agreements), we recently advised in relation to a contract with Enable Injections, Inc., for the development and clinical supply of a wearable injection device for the delivery of rozanolixizumab, an investigational antibody for the treatment of Myasthenia Gravis, a neuromuscular disease causing weakness in skeletal muscles. We have also advised UCB in business development projects including a licensing deal in the digital health space and UCB’s compliance with Human Samples legislation and GDPR. - International pharma company
Advised in relation to a collaboration with Verily Sciences, the Google Life Sciences company, for the use of Verily’s wearable technology as part of clinical trial programme. - Management sellers of Health iQ
Advised the sellers of Health iQ, a leading provider in real world data and digital solutions for healthcare and life sciences, on its sale by way of auction process to Corrona LLC, a US leader in real world evidence. We provided the entire range of legal advice, from tax through to IP, throughout the auction process, working hand in hand with Deloitte to facilitate the sale. - Optum Venture Global Partners, LP
Advised Optum, as the lead investor, investing by way of subscription for Series A Shares, in Oxford VR Limited, resulting in Optum holding 20% of the fully diluted share capital in Oxford VR. Oxford VR is technology company which has developed immersive virtual reality software aimed at treating mental health issues such as anxiety. - Healthcare apps
Advised a global healthcare company on its mobile healthcare/related apps.
